Drug Discovery

FDA approves Junshi Biosciences’ IND application for anti-CD112R antibody

The US Food and Drug Administration (FDA) has approved the investigational new drug (IND) application for Shanghai Junshi Biosciences’ anti-CD112R monoclonal antibody (TAB009/JS009) to treat advanced solid tumours.

Organon obtains license to Daré Bioscience’s Xaciato for bacterial vaginosis treatment

Women’s healthcare firm Organon has signed an agreement with Daré Bioscience for latter's Xaciato (clindamycin phosphate vaginal gel, 2%).

LifeMine secures funds to advance genomic drug discovery platform

LifeMine Therapeutics has raised $175m in a Series C financing to advance Avatar-Rx, its evolutionarily derived genomic drug discovery platform.

Affini-T Therapeutics secures funding to advance T cell therapies

Biotechnology firm Affini-T Therapeutics has raised $175m in an oversubscribed financing round for advancing T cell therapies for solid tumour patients with oncogenic driver mutations.

Triumvira Immunologics raises funds for T-cell therapy programmes

Triumvira Immunologics has completed an extension of Series A financing, which brings the total round to nearly $100m, for supporting the continued preclinical and clinical development of its T cell Antigen Coupler (TAC)-T cell therapy programmes.

Sanofi, Blackstone partner to advance multiple myeloma treatment

Sanofi has announced a collaboration with investment management firm Blackstone to advance an innovative treatment for multiple myeloma.

Erasca, Eli Lilly partner for colorectal cancer therapy trial

Erasca and Eli Lilly and Company have signed a clinical trial partnership and supply agreement to evaluate ERAS-007, an oral ERK1/2 inhibitor, in combination with Eli Lilly's anti-EGFR antibody cetuximab (ERBITUX).

Salubris secures funding to advance complex biologics for various diseases

Salubris Biotherapeutics has secured $32m in financing from Shenzhen Salubris Pharmaceuticals to advance its new complex biologics for oncology, cardiovascular and neurodegenerative diseases.

Helsinn, BridgeBio update infigratinib collaboration for oncology indications

Helsinn Group has announced an update to its existing collaboration with BridgeBio Pharma to develop, produce and commercialise infigratinib for oncology indications in the US.